Newm-035 -

The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi.

TRG-035 is a monoclonal antibody designed to stimulate the growth of a "third set" of teeth in humans who have lost them due to decay, injury, or congenital conditions. NEWM-035

Below is an overview of the development and science behind . TRG-035: The World's First Tooth Regrowth Drug The drug was developed by , a spinoff

: The treatment is administered via an intravenous injection . By neutralizing USAG-1, the drug reactivates these dormant buds, allowing the body to use its natural BMP and Wnt signaling pathways to form new, functional teeth. Clinical Development and Trials Below is an overview of the development and science behind

If clinical trials continue to show success, researchers aim to make TRG-035 commercially available by . This would offer a biological alternative to traditional prosthetic solutions like dental implants, bridges, or dentures. Japan Begins Human Trials for Tooth Regrowth Drug TRG-035